Toshiaki Sai, Executive Vice President and CFO PLAY LIST from the beginning FY2020 Q1 Financial Results Presentation Forward-Looking Statements Actions Against COVID-19 Update on Actions Against COVID-19 DS-1062 Strategic Collaboration DS-1062 Strategic Collaboration FY2020 Q1 Financial Results Overview of FY2020 Q1 Results Revenue Operating Profit Special Items Profit Attributable to Owners of the Company Revenue: Major Business Units (incl. Forex Impact) Revenue: Major Products in Japan FY2020 Forecast FY2020 Consolidated Forecast Update Business Update ENHERTU: Performance in US and Japan R&D Update 3 ADC Update DS-8201: Clinical Development Plan DS-8201: Clinical Development Plan DS-8201: DESTINY-Breast05 Study DS-8201: DESTINY-Gastric03 Study DS-8201: Gastric (DESTINY-Gastric01 Study) DS-8201: NSCLC (DESTINY-Lung01 Study) DS-8201: CRC (DESTINY-CRC01 Study) DS-1062: NSCLC (Phase 1 Study) News flow News Flow Appendix Major R&D Milestones in FY2020 Major R&D Pipeline: 3 ADCs Major R&D Pipeline: Alpha Projects for Out-Licensing Abbreviations @ Q&A Q&A 1 Q&A 2 Q&A 3 Q&A 4 Q&A 5 Q&A 6 Q&A 7 Back Next